EA
REGN icon

Euclid Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Euclid Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,800
Closed -$629K – 371
2016
Q2 		$629K Sell
1,800
-1,557
-46% -$600K 0.03% 361
2016
Q1 		$1.21M Sell
3,357
-3,534
-51% -$1.46M 0.05% 322
2015
Q4 		$3.74M Buy
+6,891
New +$3.73M 0.11% 218
2015
Q3 		– Sell
-12,375
Closed -$6.31M – 400
2015
Q2 		$6.31M Sell
12,375
-14,495
-54% -$7.07M 0.12% 215
2015
Q1 		$12.1M Buy
+26,870
New +$11.4M 0.22% 95
2014
Q4 		– Sell
-37,440
Closed -$13.5M – 475
2014
Q3 		$13.5M Sell
37,440
-710
-2% -$238K 0.1% 195
2014
Q2 		$10.8M Sell
38,150
-5,206
-12% -$1.54M 0.08% 255
2014
Q1 		$13M Buy
43,356
+12,210
+39% +$3.76M 0.1% 186
2013
Q4 		$8.57M Sell
31,146
-1,730
-5% -$498K 0.07% 257
2013
Q3 		$10.3M Buy
32,876
+7,376
+29% +$1.94M 0.1% 200
2013
Q2 		$5.74M Buy
+25,500
New +$5.94M 0.07% 272

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Euclid Advisors's REGN Position: Q3 2016 in Review

Euclid Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q3 2016, closing a stake of 1,800 shares — an estimated $629K sold.

Euclid Advisors first reported a position in REGN in Q2 2013 and held it in 11 quarters. The position peaked at $13.5M in Q3 2014. 554 funds tracked by Wall St. Rank hold REGN as of Q3 2016.

  • Euclid Advisors reported no remaining Regeneron Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Euclid Advisors sold 1,800 Regeneron Pharmaceuticals shares in Q3 2016, an estimated $629K.
  • Euclid Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 11 quarters.
  • Euclid Advisors's Regeneron Pharmaceuticals position peaked at $13.5M in Q3 2014.
  • 554 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2016.

Based on Euclid Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.